These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19076807)

  • 1. Acute paronychia caused by lapatinib therapy.
    Rigopoulos D; Gregoriou S; Belyayeva Y; Larios G; Gkouvi A; Katsambas A
    Clin Exp Dermatol; 2009 Jan; 34(1):94-5. PubMed ID: 19076807
    [No Abstract]   [Full Text] [Related]  

  • 2. Lapatinib side-effect management.
    Frankel C; Palmieri FM
    Clin J Oncol Nurs; 2010 Apr; 14(2):223-33. PubMed ID: 20350896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.
    Ena P; Fadda GM; Ena L; Farris A; Santeufemia DA
    Clin Exp Dermatol; 2008 Nov; 33(6):790-1. PubMed ID: 18627387
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical cutaneous vasculitis under lapatinib.
    Peuvrel L; Quereux G; Brocard A; Saint-Jean M; Freour E; Josselin N; Audouin AF; El Kouri C; Dreno B
    Eur J Dermatol; 2013; 23(4):540-1. PubMed ID: 23965414
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib-induced paronychia: response to autologous platelet-rich plasma.
    Kwon SH; Choi JW; Hong JS; Byun SY; Park KC; Youn SW; Huh CH; Na JI
    Arch Dermatol; 2012 Dec; 148(12):1399-402. PubMed ID: 22986691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib (Tykerb) for advanced breast cancer.
    Med Lett Drugs Ther; 2007 Sep; 49(1269):74-5. PubMed ID: 17848906
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
    Ramanathan RK; Belani CP; Singh DA; Tanaka M; Lenz HJ; Yen Y; Kindler HL; Iqbal S; Longmate J; Mack PC; Lurje G; Gandour-Edwards R; Dancey J; Gandara DR
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):777-83. PubMed ID: 19169683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib].
    Romero Carreño E; Marcos Rodríguez JA; Santana Martínez S; de la Cruz Merino L
    Farm Hosp; 2016 Mar; 40(2):134-6. PubMed ID: 26980172
    [No Abstract]   [Full Text] [Related]  

  • 9. Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
    Lin NU; Kasparian E; Morganstern DE; Beard C
    J Clin Oncol; 2009 Dec; 27(34):e218-9. PubMed ID: 19786662
    [No Abstract]   [Full Text] [Related]  

  • 10. Lapatinib: new drug. For some women with metastatic breast cancer.
    Prescrire Int; 2009 Feb; 18(99):9. PubMed ID: 19382400
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
    Harrington KJ; El-Hariry IA; Holford CS; Lusinchi A; Nutting CM; Rosine D; Tanay M; Deutsch E; Matthews J; D'Ambrosio C; Turner SJ; Pandeshwara JS; Bourhis J
    J Clin Oncol; 2009 Mar; 27(7):1100-7. PubMed ID: 19171712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
    Pikó B;
    Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
    [No Abstract]   [Full Text] [Related]  

  • 13. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
    Nakano J; Nakamura M
    J Dermatol; 2003 Mar; 30(3):261-2. PubMed ID: 12692371
    [No Abstract]   [Full Text] [Related]  

  • 14. Closing in on a cure.
    Healy B
    US News World Rep; 2006 Oct; 141(15):67. PubMed ID: 17432437
    [No Abstract]   [Full Text] [Related]  

  • 15. Magnetic resonance imaging of paronychia induced by cetuximab.
    Konheim A; Brebach E; Samuel J; Mellott A; Gandhi M; Lacouture ME
    Clin Exp Dermatol; 2009 Oct; 34(7):e258-9. PubMed ID: 19438534
    [No Abstract]   [Full Text] [Related]  

  • 16. Lapatinib shows promise for inflammatory breast cancer.
    Cancer Biol Ther; 2007 Jan; 6(1):8. PubMed ID: 17612006
    [No Abstract]   [Full Text] [Related]  

  • 17. Does toxicity predict efficacy? Insight into the mechanism of action of lapatinib.
    Fontanella C; Lederer B; Nekljudova V; Untch M; von Minckwitz G; Loibl S
    J Clin Oncol; 2014 Oct; 32(30):3458-9. PubMed ID: 25225430
    [No Abstract]   [Full Text] [Related]  

  • 18. Lapatinib for inflammatory breast cancer.
    Hall PS; Hanby A; Cameron DA
    Lancet Oncol; 2009 Jun; 10(6):538-9. PubMed ID: 19482243
    [No Abstract]   [Full Text] [Related]  

  • 19. Effective treatments for paronychia caused by oncology pharmacotherapy.
    Goto H; Yoshikawa S; Mori K; Otsuka M; Omodaka T; Yoshimi K; Yoshida Y; Yamamoto O; Kiyohara Y
    J Dermatol; 2016 Jun; 43(6):670-3. PubMed ID: 26596962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No cure in sight for the world's drug problem.
    Holmes D
    Lancet Oncol; 2009 May; 10(5):450. PubMed ID: 19418615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.